PMID- 29209324
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8(+) T Cell 
      Responses According to Human Leukocyte Antigen Class I Allotypes and 
      Intraindividual Dominance.
PG  - 1591
LID - 10.3389/fimmu.2017.01591 [doi]
LID - 1591
AB  - To define whether individual human leukocyte antigen (HLA) class I allotypes are 
      used preferentially in human cytomegalovirus (CMV)-specific cytotoxic T 
      lymphocyte responses, CD8(+) T cell responses restricted by up to six HLA class I 
      allotypes in an individual were measured in parallel using K562-based artificial 
      antigen-presenting cells expressing both CMV pp65 antigen and one of 32 HLA class 
      I allotypes (7 HLA-A, 14 HLA-B, and 11 HLA-C) present in 50 healthy Korean 
      donors. The CD8(+) T cell responses to pp65 in the HLA-C allotypes were lower 
      than responses to those in HLA-A and -B allotypes and there was no difference 
      between the HLA-A and HLA-B loci. HLA-A*02:01, -B*07:02, and -C*08:01 showed the 
      highest magnitude and frequency of immune responses to pp65 at each HLA class I 
      locus. However, HLA-A*02:07, -B*59:01, -B*58:01, -B*15:11, -C*03:02, and -C*02:02 
      did not show any immune responses. Although each individual has up to six 
      different HLA allotypes, 46% of the donors showed one allotype, 24% showed two 
      allotypes, and 2% showed three allotypes that responded to pp65. Interestingly, 
      the frequencies of HLA-A alleles were significantly correlated with the 
      positivity of specific allotypes. Our results demonstrate that specific HLA class 
      I allotypes are preferentially used in the CD8(+) T cell immune response to pp65 
      and that a hierarchy among HLA class I allotypes is present in an individual.
FAU - Hyun, Seung-Joo
AU  - Hyun SJ
AD  - Department of Microbiology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
FAU - Sohn, Hyun-Jung
AU  - Sohn HJ
AD  - Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
FAU - Lee, Hyun-Joo
AU  - Lee HJ
AD  - Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
FAU - Lee, Seon-Duk
AU  - Lee SD
AD  - Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
FAU - Kim, Sueon
AU  - Kim S
AD  - Department of Microbiology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
FAU - Sohn, Dae-Hee
AU  - Sohn DH
AD  - Department of Microbiology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
FAU - Hong, Cheol-Hwa
AU  - Hong CH
AD  - Department of Microbiology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
FAU - Choi, Haeyoun
AU  - Choi H
AD  - Department of Microbiology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
FAU - Cho, Hyun-Il
AU  - Cho HI
AD  - Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
AD  - College of Medicine, Cancer Research Institute, The Catholic University of Korea, 
      Seoul, South Korea.
FAU - Kim, Tai-Gyu
AU  - Kim TG
AD  - Department of Microbiology, College of Medicine, The Catholic University of 
      Korea, Seoul, South Korea.
AD  - Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic 
      University of Korea, Seoul, South Korea.
AD  - College of Medicine, Cancer Research Institute, The Catholic University of Korea, 
      Seoul, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20171121
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5702484
OTO - NOTNLM
OT  - CD8+ T cell
OT  - cytomegalovirus pp65
OT  - human leukocyte antigen class I
OT  - human leukocyte antigen restriction
OT  - immunodominant pattern
OT  - preferential usage
EDAT- 2017/12/07 06:00
MHDA- 2017/12/07 06:01
PMCR- 2017/01/01
CRDT- 2017/12/07 06:00
PHST- 2017/07/26 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/12/07 06:00 [entrez]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/07 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2017.01591 [doi]
PST - epublish
SO  - Front Immunol. 2017 Nov 21;8:1591. doi: 10.3389/fimmu.2017.01591. eCollection 
      2017.